Abstract 4754
Background
Breast cancer is the second leading cause of cancer deaths among women. Most women with breast cancer undergo surgery and chemotherapy and/or radiotherapy. These treatments trigger various side effects, for example, shoulder immobility, numbness or tightness, and lymphedema of the arm. Exercise-induced adaptations and better muscular performance may attenuate mentioned symptoms and side effects. The aim of this research is to determine whether there is correlation between physical exercise and the relief of symptoms predominating during radiotherapy.
Methods
Study was designed as a longitudinal sudy. The participants were female patients hospitalized at Department for Oncology at Clinical Hospital Centre Osijek, with diagnosed breast cancer, who were treated with radiotherapy after mastectomy. Research was conducted with an anonymous questionnaire, designed for the purpose of this study.
Results
There were total of 36 respondents. There was correlation between feeling of worry about the course of the disease in the beginning and the end of treatment with opinion that targeted exercises will reduce the worry (Spearman’s rho 0,630, P < 0,001). Also, there was correlation between with opinion that targeted exercises will reduce the anger and assessment that exercises reduced that feeling (Spearman’s rho 0,625, P < 0,001). After the treatment, most of the respondents evaluated the benefit from exercise in reducing pain, anger, fear and worry with 4 on a scale from 1 do 5, and they evaluated the feeling that exercises helped them with grade 5 on a scale from 1 do 5. The majority of respondents expressed that they will continue to exercise at home.
Conclusions
In general, respondents had good attitudes toward physical activity. Most of them exercise few times weekly and they think that exercise is useful. They strongly agreed that they would recommend the exercise to other patients who are suffering from this disease, that they feel that exercises helped them and that their attitude about the importance of exercise changed in a positive direction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract